CASI Pharmaceuticals, Inc. stock is up 77.32% since 30 days ago. The next earnings date is Apr 24, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 December’s closed higher than November. 100% of analysts rate it a buy.
CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL)